| Literature DB >> 27802300 |
Ruth Del Río1, Carlos Ochoa2, Ana Alarcon1,3, Juan Arnáez4, Dorotea Blanco5, Alfredo García-Alix1.
Abstract
INTRODUCTION: Perinatal management and prognostic value of clinical evaluation and diagnostic tools have changed with the generalization of therapeutic hypothermia (TH) in infants with hypoxic-ischemic encephalopathy (HIE). AIM: to ascertain the prognostic value of amplitude integrated electroencephalogram (aEEG) in neonates with HIE considering hours of life and treatment with TH.Entities:
Mesh:
Year: 2016 PMID: 27802300 PMCID: PMC5089691 DOI: 10.1371/journal.pone.0165744
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Search and section process flowchart.
Characteristics of included articles with no hypothermia treatment.
| Study and year of publication | HIE stage 1/2/3 (n) | NT | Follow-up | Neurodevelopmenta assessment. Definition of adverse outcome | Quality; Reason for reduction |
|---|---|---|---|---|---|
| NS, total n = 38 | 38 | 18 mo | Denver; Death or CP ± mental retardation | Moderate; Small sample size, stage of encephalopathy NS, variable follow-up | |
| NS, total n = 47, stage 2–3 n = 24, unspecified number of non-encephalopathic infants | 47 | 12–18 mo | NS; Death, CP or psychomotor retardation requiring special training | Moderate; Small sample size, patients with no encephalopathy or stage 1 included, unprecise definition of neurological impairment | |
| 11/7/16 | 34 | 24 mo | Griffiths and neurologic examination according to Amiel-Tison, Grenier and Touwen.; Death,,DQ <85 or CP | Moderate; Small sample size, patients with HIE stage 1 included | |
| 14/17/7, stage NA in 2 | 40 | 18–24 mo | Griffiths or Optimality Score and neurologic examination; Death, neuromotor abnormalities, Optimality Score <20 or DQ <85 | Moderate; Small sample size, patients with HIE stage 1 included | |
| NS, total n = 68 | 68 | ≥12 mo | Griffiths and neurologic examination according to Amiel-Tison, Grenier and Touwen. Alberta Infant Motor Scale in children younger than 18 mo.; Death, CP or DQ <80 | Moderate; Stage of encephalopathy NS, variable follow-up | |
| 3/17/2, normal n = 15, stage 1–2 n = 13 | 50 | 18 mo | Bayley, neurological examination, visual and hearing evaluation.; Death, CP, non-specified low Bayley score, altered vision or hearing | Low; Small sample size, patients with no encephalopathy or stage 1 included, disability not well defined | |
| 4/18/5, stage NA in 3 | 30 | 24 mo | Neurologic examination based on Touwen.; Death, severe mental and motor delay, infantile spasms or CP | Low; Retrospective, small sample size, patients with HIE stage 1 included | |
| NS, total n = 160 | 160 | 24 mo | Griffiths; Death, CP, DQ <85 | Moderate; Retrospective, stage of encephalopathy NS, variable follow-up | |
| 16/14/9 | 39 | 30 mo | Bayley II for children ≤42 mo and Leiter-R test for children > 42 mo. Neurologic evaluation according to Amiel-Tison; Death, developmental score <80 or CP | Low; Retrospective, developmental results needing adjustment for maternal education, patients with HIE stage 1 included | |
| 17/13/2 | 32 | 24 mo | Griffiths, neurologic examination and psychomotor assessment via Milani-Comparetti’s neuroevolutive assessment, Brazelton’s behavioural assessment and Prechtl’s general movement assessment. Brainstem auditory evoked responses and assessment of visual function.; Death, CP, DQ <85, hearing loss or cortical visual impairment | Moderate; Small sample size, patients with HIE stage 1 included |
CP, cerebral palsy; DQ, developmental quotient; NA, not assessable; NS, not specified; NT, cases treated in normothermia; mo = months
Characteristics of included articles with hypothermia treatment.
| Study and year of publication | HIE stage 1/2/3a (n) | NT/HT (n) | Follow-up | Neurodevelopmental assessment; Definition of adverse outcome | Quality; Reason for reduction |
|---|---|---|---|---|---|
| 3/16/4 | 0/23 | 12 mo | Serial neurological examinations and AIMS at 4 mo; Death or spasticity and AIMS score <5th percentile | Moderate; Small sample size, retrospective, patients with HIE stage 1 included, short and limited follow-up | |
| NS, total n = 74, all stage 2 or 3 | 31/43 | 18 mo | Bayley II, neurological examination, GMFCS and visual assessment; Death, MDI <70, GMFCS level 3–5 or no useful vision | High | |
| 0/8/4 | 0/12 | ≥12 mo | Griffiths; Death, CP or DQ <88.7 | Low; Small sample size, variable follow-up | |
| 0/71/37 | 51/57 | 18 mo | Bayley II, neurological examination, GMFCS, hearing and visual assessment; Death; MDI 70–84 and either a GMFCS level of 2, hearing impairment with no amplification or persistent seizure disorder; MDI <70; GMFCS level 3–5; hearing impairment requiring hearing aids or blindness | High | |
| 0/6/4 | 0/10 | 8–24 mo | Bayley II; Death, CP, MDI or PDI <70 | Low; Retrospective, inconsistent follow-up | |
| NS, total n = 70, all stage 2 or 3 | 0/70 | 18–24 mo | Bayley II; Death, MDI or PDI <70 | Moderate; Retrospective | |
| NS, total n = 314, all stage 2 or 3 | 158/156 | 18 mo | Bayley II, neurological examination, GMFCS and visual assessmentDeath, CP with GMFCS level 3–5, MDI <70 or bilateral cortical visual impairment | High |
AIMS, Alberta Infant Motor Scale; CP, cerebral palsy; DQ, developmental quotient; GMFCS, Gross Motor Function Classification System; MDI, mental developmental index; NT/HT, ratio of cases treated in normothermia/receiving therapeutic hypothermia; PDI, psychomotor developmental index; mo, months
Fig 2Forest plot for all included studies, considering hours of life and treatment or not with hypothermia.
Fig 3QUADAS 2 assessment of included papers.
Fig 4ROC curves for different hours of life.
Pooled sensitivity and specificity, diagnostic odds ratio and likelihood ratios with confidence intervals for abnormal aEEG and death or moderate/severe disability, patients receiving and not receiving TH.
| aEEG-Death/Seriousdisability | Normothermia | Hypothermia | |
|---|---|---|---|
| 12 (671) | 7 (360) | ||
| 0.87 | 0.94 | ||
| 0.84 (0.78 to 0.88) | 0.95 (0.9 to 0.98) | ||
| 0.79 (0.63 to 0.89) | 0.61 (0.51 to 0.69) | ||
| 4.34 (2.31 to 7.73) | 1.57 (1.37 to 1.85) | ||
| 0.2 (0.14 to 0.29) | 0.12 (0.05 to 0.25) | ||
| 22.2 (8.85 to 46.2) | 15.3 (5.5 to 32.4) | ||
| 5 (267) | 4 (141) | ||
| 0.95 | 0.86 | ||
| 0.84 (0.77 to 0.89) | 0.89 (0.71 to 0.96) | ||
| 0.96 (0.89 to 0.98) | 0.65 (0.46 to 0.81) | ||
| 24.2 (7.48 to 59.3) | 2.76 (1.48 to 5.27) | ||
| 0.16 (0.1 to 0.23) | 0.19 (0.04 to 0.53) | ||
| 155 (41.6 to 451) | 23.9 (2.65 to 95.7) | ||
| 3 (76) | 3 (126) | ||
| 0.95 | 0.93 | ||
| 0.79 (0.59 to 0.9) | 0.89 (0.76 to 0.95) | ||
| 0.95 (0.81 to 0.99) | 0.84 (0.74 to 0.9) | ||
| 26.6 (4.43 to 94.9) | 5.73 (3.35 to 9.43) | ||
| 0.23 (0.09 to 0.44) | 0.14 (0.05 to 0.28) | ||
| 141 (13.6 to 589) | 51.2 (13.2 to 130) | ||
| 3 (77) | 3 (123) | ||
| 0.95 | 0.85 | ||
| 0.76 (0.61 to 0.86) | 0.79 (0.64 to 0.89) | ||
| 0.95 (0.79 to 0.99) | 0.93 (0.85 to 0.97) | ||
| 23.3 (3.55 to 85.7) | 14.4 (5.51 to 32.5) | ||
| 0.26 (0.15 to 0.41) | 0.22 (0.11 to 0.37) | ||
| 101 (11.3 to 385) | 73.7 (17.2 to 200) | ||
| 3 (64) | 3 (119) | ||
| 0.82 | 0.91 | ||
| 0.73 (0.54 to 0.85) | 0.61 (0.45 to 0.75) | ||
| 0.89 (0.58 to 0.97) | 0.97 (0.9 to 0.99) | ||
| 9.04 (1.69 to 31.6) | 24.3 (5.89 to 71.3) | ||
| 0.32 (0.17 to 0.56) | 0.39 (0.25 to 0.57) | ||
| 31.8 (3.36 to 119) | 65.6 (12.7 to 203) | ||
AUC: area under the curve; DOR diagnostic odds ratio; LR likelihood ratio
Fig 5Likelihood ratios and post-test probability of abnormal aEEG and adverse neurological outcome, patients not treated with hypothermia according to hours of life.
Fig 6Likelihood ratios and post-test probability of abnormal aEEG and adverse neurological outcome, patients treated with hypothermia according to hours of life.